Unknown

Dataset Information

Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.


ABSTRACT:

Purpose

To improve the outcomes of patients with castration-resistant prostate cancer (CRPC), there is an urgent need for more effective therapies and approaches that individualize specific treatments for patients with CRPC. These studies compared the novel taxane cabazitaxel with the previous generation docetaxel, and aimed to determine which tumors are most likely to respond.

Experimental design

Cabazitaxel and docetaxel were compared via in vitro modeling to determine the molecular mechanism, biochemical and cell biologic impact, and cell proliferation, which was further assessed ex vivo in human tumor explants. Isogenic pairs of RB knockdown and control cells were interrogated in vitro and in xenograft tumors for cabazitaxel response.

Results

The data herein show

SUBMITTER: de Leeuw R 

PROVIDER: S-EPMC4333741 | biostudies-literature | 2015 Feb

REPOSITORIES: biostudies-literature